{"title":"在HIV/AIDS患者中，以富马酸替诺福韦二奥proxil为基础的治疗结果和不良事件与以齐多夫定为基础的治疗方案的比较:观察性研究的系统回顾和荟萃分析","authors":"Adane Teshome Kefale, Tegene Legese Dadi, Tessema Tsehay Biru, Teshale Ayele Mega","doi":"10.2174/1874613601812010038","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Findings from different studies report inferior clinical and virologic efficacy with TDF/3TC/NVP. But, some studies show that, there was no statistically significant difference in mortality among ZDV and TDF based regimens. The objective of this review was to systematically identify, appraise and synthesize the best available evidence on efficacy and safety of TDF based regimen as compared to ZDV based regimens.</p><p><strong>Methods: </strong>A three-step search strategy was used to locate published and unpublished studies. First, an initial limited search of google was undertaken followed by analysis of text words. A second extensive search was undertaken. We searched the PubMed, EMBASE, Google Scholar, Medline, and CINHAL. We did the initial search for articles on July 11-18, 2016, and updated the results on May 13, 2017.Third, the reference lists of all identified articles was searched for additional studies.</p><p><strong>Results: </strong>ZDV based regimens had better outcome on prevention of mortality (OR=1.31, 95%CI (1.14, 1.50), I<sup>2</sup> = 0%, Chi<sup>2</sup> = 2.51), and lower virologic failure (OR = 1.44, 95% CI [1.18, 1.76], chi<sup>2</sup> = 5.91, P= 0.003, I<sup>2</sup> =83%) while, TDF based regimens were more tolerable (OR=0.15, 95%CI (0.08, 0.30), I<sup>2</sup> = 40%, Chi<sup>2</sup> = 3.31). The difference in incidence of opportunistic infection is not significant (OR = 0.83, 95% CI [0.52, 1.32], chi<sup>2</sup> = 0.11, P= 0.42, I<sup>2</sup> =0%).</p><p><strong>Conclusion: </strong>There is lower mortality and lower virologic failure in ZDV group, but better safety profile among TDF based regimens.</p>","PeriodicalId":515834,"journal":{"name":"The Open AIDS Journal","volume":"12 ","pages":"38-52"},"PeriodicalIF":0.0000,"publicationDate":"2018-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1874613601812010038","citationCount":"3","resultStr":"{\"title\":\"Treatment Outcome and Adverse Events of Tenofovir Disoproxil Fumarate Based Regimens as Compared to Zidovudine Based Regimens Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis of Observational Studies.\",\"authors\":\"Adane Teshome Kefale, Tegene Legese Dadi, Tessema Tsehay Biru, Teshale Ayele Mega\",\"doi\":\"10.2174/1874613601812010038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Findings from different studies report inferior clinical and virologic efficacy with TDF/3TC/NVP. But, some studies show that, there was no statistically significant difference in mortality among ZDV and TDF based regimens. The objective of this review was to systematically identify, appraise and synthesize the best available evidence on efficacy and safety of TDF based regimen as compared to ZDV based regimens.</p><p><strong>Methods: </strong>A three-step search strategy was used to locate published and unpublished studies. First, an initial limited search of google was undertaken followed by analysis of text words. A second extensive search was undertaken. We searched the PubMed, EMBASE, Google Scholar, Medline, and CINHAL. We did the initial search for articles on July 11-18, 2016, and updated the results on May 13, 2017.Third, the reference lists of all identified articles was searched for additional studies.</p><p><strong>Results: </strong>ZDV based regimens had better outcome on prevention of mortality (OR=1.31, 95%CI (1.14, 1.50), I<sup>2</sup> = 0%, Chi<sup>2</sup> = 2.51), and lower virologic failure (OR = 1.44, 95% CI [1.18, 1.76], chi<sup>2</sup> = 5.91, P= 0.003, I<sup>2</sup> =83%) while, TDF based regimens were more tolerable (OR=0.15, 95%CI (0.08, 0.30), I<sup>2</sup> = 40%, Chi<sup>2</sup> = 3.31). The difference in incidence of opportunistic infection is not significant (OR = 0.83, 95% CI [0.52, 1.32], chi<sup>2</sup> = 0.11, P= 0.42, I<sup>2</sup> =0%).</p><p><strong>Conclusion: </strong>There is lower mortality and lower virologic failure in ZDV group, but better safety profile among TDF based regimens.</p>\",\"PeriodicalId\":515834,\"journal\":{\"name\":\"The Open AIDS Journal\",\"volume\":\"12 \",\"pages\":\"38-52\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2174/1874613601812010038\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open AIDS Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874613601812010038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open AIDS Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874613601812010038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment Outcome and Adverse Events of Tenofovir Disoproxil Fumarate Based Regimens as Compared to Zidovudine Based Regimens Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis of Observational Studies.
Background: Findings from different studies report inferior clinical and virologic efficacy with TDF/3TC/NVP. But, some studies show that, there was no statistically significant difference in mortality among ZDV and TDF based regimens. The objective of this review was to systematically identify, appraise and synthesize the best available evidence on efficacy and safety of TDF based regimen as compared to ZDV based regimens.
Methods: A three-step search strategy was used to locate published and unpublished studies. First, an initial limited search of google was undertaken followed by analysis of text words. A second extensive search was undertaken. We searched the PubMed, EMBASE, Google Scholar, Medline, and CINHAL. We did the initial search for articles on July 11-18, 2016, and updated the results on May 13, 2017.Third, the reference lists of all identified articles was searched for additional studies.
Results: ZDV based regimens had better outcome on prevention of mortality (OR=1.31, 95%CI (1.14, 1.50), I2 = 0%, Chi2 = 2.51), and lower virologic failure (OR = 1.44, 95% CI [1.18, 1.76], chi2 = 5.91, P= 0.003, I2 =83%) while, TDF based regimens were more tolerable (OR=0.15, 95%CI (0.08, 0.30), I2 = 40%, Chi2 = 3.31). The difference in incidence of opportunistic infection is not significant (OR = 0.83, 95% CI [0.52, 1.32], chi2 = 0.11, P= 0.42, I2 =0%).
Conclusion: There is lower mortality and lower virologic failure in ZDV group, but better safety profile among TDF based regimens.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
